Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib
and erlotinib, are the first targeted therapy drugs approved for the treatment of advanced non …

The Src family of kinases has nine known members, all of which are nonreceptor tyrosine
kinases involved in signal transduction in both normal and cancer cells. Interest in these …

Mutation-specific cancer therapy has shown promising clinical efficacy. In non–small-cell
lung cancer (NSCLC), the presence of mutations in the epidermal growth factor receptor …

Epidermal growth factor receptor (EGFR) is one of the important and valuable drug targets.
Overexpression of EGFR is associated with the development of many types of cancer. In this …

Purpose: Signal transducer and activator of transcription-3 (STAT3) is downstream of growth
factor and cytokine receptors, and regulates key oncogenic pathways in nonsmall cell lung …

PURPOSE: To describe the ocular effects associated with the administration of the systemic
epidermal growth factor receptor (EGFR) inhibitors panitumumab and erlotinib. DESIGN …

Preexisting and acquired resistance to epidermal growth factor receptor (EGFR) inhibitors
limits their clinical usefulness in patients with advanced non–small cell lung cancer …

Carcinomas of an unknown primary site (CUP) are heterogeneous tumours with a median
survival of only 8 months. Tyrosine kinase inhibitors are promising new drugs. The aim of …

Quality initiatives and guidelines advocate an integrated palliative care-oncology model.
The vision of the American Society of Clinical Oncology (ASCO) of personalized medicine …

Controlling aberrant kinase-mediated cellular signaling is a major strategy in cancer
therapy; successful protein kinase inhibitors such as Tarceva and Gleevec verify this …